What is THERIVA BIOLOGICS INC's earnings per share (EPS)?

THERIVA BIOLOGICS INC (TOVX) reported diluted earnings per share of -$2.08 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

THERIVA BIOLOGICS INC (TOVX) Financials

TOVX

FY2025 annual

Net Income -$23.7M +7.5% YoY

EPS (Diluted) -$2.08 YoY not available

Free Cash Flow -$16.7M +1.4% YoY

Operating Cash Flow -$16.7M +1.6% YoY

Market Cap $11.6M as of Sep 4, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.0x on $12.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 4, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TOVX SEC filings page.

This page shows THERIVA BIOLOGICS INC (TOVX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TOVX FY2025 2026-08-29

Theriva’s development spending is funded by external capital, while reported revenue is unavailable and operating cash flow remains negative.

The near match between -$16.7M of operating cash flow and -$16.7M of free cash flow in FY2025 shows that cash consumption is operational, not primarily a consequence of heavy capital investment. Net loss was -$23.7M, so the gap between accounting loss and cash outflow points to non-cash or working-capital effects rather than reinvestment intensity.

The cost base changed shape: R&D spending fell from $14.3M in FY2023 to $8.6M in FY2025. Meanwhile, SG&A rose from $7.1M in FY2023 to $15.4M, shifting reported spending toward administrative and selling functions.

FY2025 financing inflows of $18.2M were roughly comparable to operating cash flow of -$16.7M, indicating that external funding offset ongoing operating needs. The reported liquidity measure was 9.4 months of the latest annual operating outflow, describing a balance-sheet comparison rather than internally generated funding.

Financial Health Signals

Financial health score not available

THERIVA BIOLOGICS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/7

THERIVA BIOLOGICS INC passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

THERIVA BIOLOGICS INC reported a net loss of $23.7M while operations used $16.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

THERIVA BIOLOGICS INC reported an operating loss of $24.1M against $61K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$3.3M

YoY+75.0%

QoQ-55.5%

THERIVA BIOLOGICS INC's EBITDA was -$3.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 75.0% from the same quarter a year earlier. Against the prior quarter it is down 55.5%.

Net Income

-$3.2M

YoY+75.4%

QoQ-57.4%

THERIVA BIOLOGICS INC reported -$3.2M in net income in Q2 2026. This represents an increase of 75.4% from the same quarter a year earlier. Against the prior quarter it is down 57.4%.

EPS (Diluted)

-$0.07

QoQ-40.0%

THERIVA BIOLOGICS INC earned -$0.07 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 40.0%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$11.3M

YoY-6.5%

QoQ-21.4%

5Y CAGR-31.3%

10Y CAGR+1.2%

THERIVA BIOLOGICS INC held $11.3M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

46M

QoQ0.0%

5Y CAGR-19.1%

10Y CAGR-6.6%

THERIVA BIOLOGICS INC had 46M shares outstanding in Q2 2026. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-26.4%

YoY+96.5pp

QoQ-13.1pp

THERIVA BIOLOGICS INC's ROE was -26.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 96.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 13.1 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$1.3M

YoY-35.1%

QoQ+257.2%

THERIVA BIOLOGICS INC invested $1.3M in research and development in Q2 2026. This represents a decrease of 35.1% from the same quarter a year earlier. Against the prior quarter it is up 257.2%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

TOVX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TOVX quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
R&D Expenses	N/A	$8.6M-28.5%	$12.0M-15.9%	$14.3M+22.1%	$11.7M+50.3%	$7.8M+52.0%	$5.1M-53.7%	$11.1M-6.4%	$11.8M-36.9%	$18.8M-35.5%	$29.1M-11.5%	$32.9M+127.1%	$14.5M+122.7%	$6.5M-47.0%	$12.3M+267.9%	$3.3M
SG&A Expenses	N/A	$15.4M+108.9%	$7.4M+3.9%	$7.1M-27.8%	$9.9M+52.3%	$6.5M+28.7%	$5.0M+9.8%	$4.6M-20.0%	$5.7M-23.3%	$7.5M-26.4%	$10.1M+25.6%	$8.1M+34.3%	$6.0M+3.1%	$5.8M+16.4%	$5.0M+93.7%	$2.6M
Operating Income	N/A	-$24.1M+8.7%	-$26.3M-22.9%	-$21.4M+0.7%	-$21.6M-51.2%	-$14.3M-40.5%	-$10.2M+35.1%	-$15.7M+10.9%	-$17.6M+33.1%	-$26.3M+33.1%	-$39.3M+4.2%	-$41.0M-99.9%	-$20.5M-66.2%	-$12.3M+28.7%	-$17.3M	N/A
EBITDA	N/A	-$23.9M+8.6%	-$26.2M-23.1%	-$21.3M+0.9%	-$21.5M-51.5%	-$14.2M-42.5%	-$10.0M+35.4%	-$15.4M+10.8%	-$17.3M+33.5%	-$26.0M+33.5%	-$39.1M+4.4%	-$40.9M-99.7%	-$20.5M-66.6%	-$12.3M+28.7%	-$17.2M	N/A
Interest Expense	N/A	$61K+916.7%	$6K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	$0+100.0%	-$1.6M-15.1%	-$1.4M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$23.7M+7.5%	-$25.7M-39.8%	-$18.3M+6.8%	-$19.7M-38.0%	-$14.3M-42.1%	-$10.0M+34.4%	-$15.3M-14.5%	-$13.4M+11.9%	-$15.2M+44.3%	-$27.3M+37.7%	-$43.7M-121.1%	-$19.8M-60.6%	-$12.3M+27.8%	-$17.1M-109.4%	-$8.1M
EPS (Basic)	N/A	-$2.08+89.1%	-$19.03+33.2%	-$28.48-2074.0%	-$1.31+31.1%	-$1.90-187.9%	-$0.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.73	-$2.08	-$19.03	-$28.48	-$1.31	-$1.90	-$0.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	12M	1M	644,282	15M	12M	19M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	$300K	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.3M-35.1%	$355K-88.0%	N/A	$2.6M-6.7%	$2.0M-33.9%	$3.0M-14.2%	N/A	$2.7M-31.8%
SG&A Expenses	$2.0M-81.9%	$2.1M+43.0%	N/A	$1.9M-17.9%	$11.2M+662.0%	$1.4M-25.0%	N/A	$2.3M+985.8%
Operating Income	-$3.3M+74.9%	-$2.1M+51.8%	N/A	-$4.4M+43.7%	-$13.1M-54.7%	-$4.4M+18.1%	N/A	-$7.9M-87.0%
EBITDA	-$3.3M+75.0%	-$2.1M+52.1%	N/A	-$4.4M+43.8%	-$13.1M-55.1%	-$4.4M+18.0%	N/A	-$7.9M-87.6%
Interest Expense	$17K+6.3%	$16K+33.3%	N/A	N/A	$16K	$12K	N/A	N/A
Net Income	-$3.2M+75.4%	-$2.0M+52.7%	N/A	-$4.4M+43.6%	-$13.1M-57.0%	-$4.3M+16.3%	N/A	-$7.7M-133.9%
EPS (Basic)	-$0.07+96.4%	-$0.05+96.8%	$1.30-76.1%	-$0.45+93.4%	-$1.93+82.0%	-$1.55+79.4%	$5.44+167.2%	-$6.81-40.4%
EPS (Diluted)	-$0.07	-$0.05	$1.30	-$0.45	-$1.93	-$1.55	$5.44	-$6.81
Diluted Shares (Avg)	46M	41M	N/A	10M	7M	3M	N/A	1M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

TOVX Balance Sheet

TOVX quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$38.2M+8.2%	$35.4M-36.0%	$55.2M-23.2%	$71.9M+2.1%	$70.4M+736.7%	$8.4M-51.2%	$17.2M-42.8%	$30.1M+60.0%	$18.8M-16.3%	$22.5M-27.1%	$30.8M+61.1%	$19.1M+17.8%	$16.3M+21.1%	$13.4M+79.5%	$7.5M
Current Assets	$17.5M+7.3%	$16.3M-40.6%	$27.4M-39.8%	$45.5M-33.9%	$68.9M+767.9%	$7.9M-51.7%	$16.4M-44.3%	$29.5M+64.5%	$17.9M-16.8%	$21.6M-28.9%	$30.3M+59.1%	$19.1M+17.6%	$16.2M+30.1%	$12.5M+75.0%	$7.1M
Cash & Equivalents	$13.1M+12.5%	$11.6M-49.9%	$23.2M-44.5%	$41.8M-37.9%	$67.3M+981.2%	$6.2M-58.6%	$15.0M-48.0%	$28.9M+69.0%	$17.1M-10.2%	$19.1M-8.5%	$20.8M+18.8%	$17.5M+19.8%	$14.6M+46.9%	$10.0M+49.1%	$6.7M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$405K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	$0-100.0%	$5.7M+3.2%	$5.5M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$22.9M+40.4%	$16.3M+4.9%	$15.5M-10.3%	$17.3M+248.9%	$5.0M-62.4%	$13.2M-14.5%	$15.4M+17.9%	$13.1M-35.7%	$20.3M+0.4%	$20.2M+27.8%	$15.8M+65.2%	$9.6M+833.6%	$1.0M+160.0%	$395K-5.3%	$417K
Current Liabilities	$10.0M+32.0%	$7.6M+12.6%	$6.7M-4.6%	$7.1M+98.6%	$3.6M+19.8%	$3.0M-43.8%	$5.3M+55.9%	$3.4M-65.4%	$9.8M-50.4%	$19.8M+26.9%	$15.6M+62.4%	$9.6M+833.6%	$1.0M+160.0%	$395K-5.3%	$417K
Non-Current Liabilities	$12.8M+47.6%	$8.7M-1.0%	$8.8M-14.2%	$10.2M+629.7%	$1.4M-86.3%	$10.2M+0.7%	$10.1M+4.6%	$9.7M-8.1%	$10.5M+2042.5%	$492K+84.3%	$267K	$0	$0	$0	$0
Long-Term Debt	$1.7M+1716.3%	$92K-43.2%	$162K-26.7%	$221K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$15.4M-19.3%	$19.1M-48.4%	$37.0M-28.7%	$51.8M-20.8%	$65.4M+1472.1%	-$4.8M-361.8%	$1.8M-89.3%	$17.1M+1240.9%	-$1.5M-138.9%	$3.8M-76.0%	$16.1M+68.0%	$9.6M-37.3%	$15.2M+16.9%	$13.0M+84.6%	$7.1M
Retained Earnings	-$358.7M-7.1%	-$335.0M-8.3%	-$309.3M-6.3%	-$291.0M-7.3%	-$271.3M-9.3%	-$248.1M-5.3%	-$235.5M-7.3%	-$219.5M-13.0%	-$194.2M-12.9%	-$172.0M-18.8%	-$144.8M-43.3%	-$101.0M-24.3%	-$81.3M-17.9%	-$68.9M-32.9%	-$51.9M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$34.9M-2.7%	$38.2M+18.9%	$38.2M+8.2%	$30.8M-23.1%	$35.8M-15.5%	$32.2M-34.0%	$35.4M-36.0%	$40.1M-34.8%
Current Assets	$13.7M-7.3%	$16.8M+34.3%	$17.5M+7.3%	$9.9M-49.3%	$14.7M-25.2%	$12.5M-42.4%	$16.3M-40.6%	$19.5M-43.8%
Cash & Equivalents	$11.3M-6.5%	$14.4M+44.1%	$13.1M+12.5%	$7.5M-54.1%	$12.1M-27.0%	$10.0M-45.2%	$11.6M-49.9%	$16.4M-47.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	N/A
Total Liabilities	$22.7M-10.1%	$22.8M+37.1%	$22.9M+40.4%	$24.1M+55.7%	$25.2M+71.0%	$16.7M+14.1%	$16.3M+4.9%	$15.5M-12.4%
Current Liabilities	$12.1M-2.3%	$10.3M+26.0%	$10.0M+32.0%	$11.0M+50.3%	$12.4M+81.0%	$8.1M+35.6%	$7.6M+12.6%	$7.3M-16.2%
Non-Current Liabilities	$10.6M-17.6%	$12.6M+47.8%	$12.8M+47.6%	$13.1M+60.7%	$12.8M+62.3%	$8.5M-1.0%	$8.7M-1.0%	$8.2M-8.6%
Long-Term Debt	N/A	N/A	$1.7M+1716.3%	N/A	N/A	N/A	$92K-43.2%	N/A
Total Equity	$12.2M+14.7%	$15.4M-0.6%	$15.4M-19.3%	$6.7M-72.6%	$10.6M-59.0%	$15.5M-50.6%	$19.1M-48.4%	$24.6M-40.1%
Retained Earnings	-$364.0M-3.3%	-$360.8M-6.3%	-$358.7M-7.1%	-$356.7M-7.9%	-$352.4M-9.2%	-$339.3M-7.9%	-$335.0M-8.3%	-$330.5M-8.8%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable.

TOVX Cash Flow Statement

TOVX quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$12.7M	-$16.7M+1.6%	-$16.9M+10.8%	-$19.0M+0.5%	-$19.1M-48.0%	-$12.9M-5.9%	-$12.2M+12.3%	-$13.9M+19.7%	-$17.3M+14.5%	-$20.2M+27.6%	-$27.9M+28.3%	-$38.9M-141.9%	-$16.1M-108.3%	-$7.7M+13.4%	-$8.9M-210.1%	-$2.9M
Depreciation & Amortization	N/A	$108K-21.2%	$137K+1.5%	$135K+58.8%	$85K-2.3%	$87K-56.7%	$201K-16.3%	$240K-11.8%	$272K+11.0%	$245K+56.1%	$157K+118.1%	$72K+260.0%	$20K-53.5%	$43K-31.7%	$63K-56.3%	$144K
Stock-Based Compensation	N/A	$654K-2.5%	$671K+21.6%	$552K+16.2%	$475K+14.2%	$416K+18.9%	$350K+2.9%	$340K-83.6%	$2.1M-39.2%	$3.4M-15.0%	$4.0M+25.4%	$3.2M+30.1%	$2.5M+47.3%	$1.7M-9.8%	$1.9M+90.2%	$973K
Capital Expenditures	N/A	$35K+3400.0%	$1K-99.5%	$202K+74.1%	$116K+728.6%	$14K+55.6%	$9K	$0-100.0%	$7K-96.7%	$212K-62.7%	$569K+13.6%	$501K+943.8%	$48K+33.3%	$36K+260.0%	$10K	$0
Free Cash Flow	N/A	-$16.7M+1.4%	-$16.9M+11.8%	-$19.2M0.0%	-$19.2M-48.8%	-$12.9M-6.0%	-$12.2M+12.2%	-$13.9M+19.7%	-$17.3M+15.3%	-$20.4M+28.3%	-$28.5M+27.7%	-$39.4M-144.3%	-$16.1M-108.0%	-$7.8M+13.1%	-$8.9M-210.5%	-$2.9M
Investing Cash Flow	N/A	-$35K-3400.0%	-$1K+99.5%	-$202K+95.4%	-$4.4M-31300.0%	-$14K-55.6%	-$9K	$0+100.0%	-$7K+96.7%	-$212K+62.7%	-$569K-13.6%	-$501K-943.8%	-$48K-33.3%	-$36K-260.0%	-$10K+86.7%	-$75K
Financing Cash Flow	$12.2M	$18.2M+231.0%	$5.5M+779.4%	$625K+132.4%	-$1.9M-102.6%	$74.0M+2103.1%	$3.4M	$0-100.0%	$29.1M+57.4%	$18.5M-30.8%	$26.7M-37.4%	$42.7M+124.3%	$19.0M+53.1%	$12.4M+1.8%	$12.2M+74.8%	$7.0M
Share Buybacks	N/A	N/A	N/A	$0-100.0%	$288K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$3.1M+34.5%	-$2.5M+48.4%	-$2.9M+38.6%	-$4.3M-10.4%	-$4.7M-36.5%	-$4.8M+2.6%	-$4.7M+28.3%	-$3.9M-32.5%
Depreciation & Amortization	$24K-11.1%	$24K-7.7%	$27K0.0%	$28K-15.2%	$27K-28.9%	$26K-33.3%	$27K-30.8%	$33K+3.1%
Stock-Based Compensation	N/A	$135K+35.0%	N/A	N/A	N/A	$100K-37.5%	N/A	N/A
Capital Expenditures	N/A	N/A	$0	$19K	N/A	N/A	$0-100.0%	$0-100.0%
Free Cash Flow	N/A	N/A	-$2.9M+38.6%	-$4.3M-10.9%	N/A	N/A	-$4.7M+28.9%	-$3.9M-27.0%
Investing Cash Flow	N/A	N/A	$0	-$19K	N/A	N/A	$0+100.0%	$0+100.0%
Financing Cash Flow	-$14K-100.2%	$3.9M+25.8%	$8.5M+120728.6%	-$148K-104.0%	$6.8M	$3.1M	$7K+100.5%	$3.7M+371500.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TOVX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TOVX quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Return on Equity	-154.3%-19.8pp	-134.5%-84.9pp	-49.6%-11.7pp	-38.0%-16.2pp	-21.8%	N/A	-840.4%-762.0pp	-78.3%	N/A	-708.8%-436.4pp	-272.5%-65.5pp	-207.0%-126.2pp	-80.9%+50.1pp	-131.0%-15.6pp	-115.4%
Return on Assets	-62.1%+10.5pp	-72.6%-39.3pp	-33.2%-5.8pp	-27.4%-7.1pp	-20.3%+99.1pp	-119.4%-30.6pp	-88.8%-44.4pp	-44.4%+36.2pp	-80.5%+40.6pp	-121.1%+20.7pp	-141.8%-38.5pp	-103.3%-27.6pp	-75.8%+51.4pp	-127.2%-18.1pp	-109.0%
Current Ratio	1.74-0.4x	2.15-1.9x	4.07-2.4x	6.45-12.9x	19.37+16.7x	2.67-0.4x	3.11-5.6x	8.72+6.9x	1.83+0.7x	1.09-0.9x	1.950.0x	1.99-13.8x	15.79-15.8x	31.55+14.5x	17.08
Debt-to-Equity	0.11+0.1x	0.000.0x	0.000.0x	0.00-0.1x	0.08	N/A	8.46+7.7x	0.77	N/A	5.27+4.3x	0.990.0x	1.00+0.9x	0.070.0x	0.030.0x	0.06
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.00

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	-709.0%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	-681.3%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-26.4%+96.5pp	-13.3%+14.6pp	N/A	-64.7%-33.4pp	-122.9%-90.8pp	-27.9%-11.5pp	N/A	-31.4%-23.3pp
Return on Assets	-9.2%+27.2pp	-5.3%+8.1pp	N/A	-14.1%+5.1pp	-36.4%-16.8pp	-13.4%-2.8pp	N/A	-19.3%-13.9pp
Current Ratio	1.13-0.1x	1.63+0.1x	1.74-0.4x	0.90-1.8x	1.19-1.7x	1.53-2.1x	2.15-1.9x	2.67-1.3x
Debt-to-Equity	1.86-0.5x	1.48+0.4x	0.11+0.1x	3.58+2.9x	2.37+1.8x	1.08+0.6x	0.000.0x	0.63+0.6x
Asset Turnover	N/A	0.01	N/A	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
THERIVA BIOLOGICS INC TOVX	FY2025	N/A	-$23.7M	N/A	$11.6M	—
Xortx Therapeutics Inc XRTX	FY2025	N/A	-$2.7M	N/A	$4.2M	—
Galecto Inc. GLTO	FY2025	N/A	-$209.8M	N/A	$1.7B	—
Entero Therapeutics ENTO	FY2025	$36K	-$6.4M	N/A	$10.1M	—
Quoin Pharmaceuticals Ltd QNRX	FY2025	N/A	-$15.8M	N/A	$14.6M	—
Azitra Inc AZTR	FY2025	$0	-$11.0M	N/A	$10.9M	—

Where THERIVA BIOLOGICS INC Ranks

Frequently Asked Questions

Is THERIVA BIOLOGICS INC profitable?

No, THERIVA BIOLOGICS INC (TOVX) reported a net income of -$23.7M in fiscal year 2025.

What is THERIVA BIOLOGICS INC's EBITDA?

THERIVA BIOLOGICS INC (TOVX) had EBITDA of -$23.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does THERIVA BIOLOGICS INC have?

As of fiscal year 2025, THERIVA BIOLOGICS INC (TOVX) had $13.1M in cash and equivalents against $1.7M in long-term debt.

What is THERIVA BIOLOGICS INC's return on equity (ROE)?

THERIVA BIOLOGICS INC (TOVX) has a return on equity of -154.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is THERIVA BIOLOGICS INC's free cash flow?

THERIVA BIOLOGICS INC (TOVX) recorded an outflow of $16.7M in free cash flow during fiscal year 2025. This represents a 1.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is THERIVA BIOLOGICS INC's operating cash flow?

THERIVA BIOLOGICS INC (TOVX) recorded an outflow of $16.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are THERIVA BIOLOGICS INC's total assets?

THERIVA BIOLOGICS INC (TOVX) had $38.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are THERIVA BIOLOGICS INC's capital expenditures?

THERIVA BIOLOGICS INC (TOVX) invested $35K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does THERIVA BIOLOGICS INC spend on research and development?

THERIVA BIOLOGICS INC (TOVX) invested $8.6M in research and development during fiscal year 2025.

How many shares does THERIVA BIOLOGICS INC have outstanding?

THERIVA BIOLOGICS INC (TOVX) had 46M shares outstanding as of fiscal year 2025.

What is THERIVA BIOLOGICS INC's current ratio?

THERIVA BIOLOGICS INC (TOVX) had a current ratio of 1.74 as of fiscal year 2025, which is generally considered healthy.

What is THERIVA BIOLOGICS INC's debt-to-equity ratio?

THERIVA BIOLOGICS INC (TOVX) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is THERIVA BIOLOGICS INC's return on assets (ROA)?

THERIVA BIOLOGICS INC (TOVX) had a return on assets of -62.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is THERIVA BIOLOGICS INC's P/E ratio?

THERIVA BIOLOGICS INC (TOVX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $11.6M as of Sep 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is THERIVA BIOLOGICS INC's price-to-sales ratio?

THERIVA BIOLOGICS INC (TOVX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $11.6M as of Sep 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does THERIVA BIOLOGICS INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, THERIVA BIOLOGICS INC (TOVX) held $13.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $16.7M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is THERIVA BIOLOGICS INC's Piotroski F-Score?

THERIVA BIOLOGICS INC (TOVX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are THERIVA BIOLOGICS INC's earnings high quality?

THERIVA BIOLOGICS INC (TOVX) reported a net loss of $23.7M while operations used $16.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can THERIVA BIOLOGICS INC cover its interest payments?

THERIVA BIOLOGICS INC (TOVX) reported an operating loss of $24.1M against $61K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.